Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Centre, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland; Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Liverpool Centre for Cardiovascular Science (LCCS), Liverpool, UK.
Cell Rep Med. 2024 Sep 17;5(9):101726. doi: 10.1016/j.xcrm.2024.101726.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a therapeutic target for dyslipidemia and atherosclerotic cardiovascular disease (ASCVD). Two recent studies published by Fang et al. and Zhang et al. in Cell Reports Medicine and Cell Reports, respectively, show the efficacy of peptide vaccines in eliciting an antibody response against PCSK9 and reducing plasma cholesterol levels.
脯氨酰肽链内切酶枯草溶菌素 9（PCSK9）是治疗血脂异常和动脉粥样硬化性心血管疾病（ASCVD）的靶点。方等人和张等人最近分别在《细胞报告医学》和《细胞报告》上发表的两项研究表明，肽疫苗在引发针对 PCSK9 的抗体反应和降低血浆胆固醇水平方面具有疗效。
